symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
SZLSF,0.0385,0.820916,1400,4096092,0,0.03-0.1019,0.0085,StageZero Life Sciences Ltd.,USD,0001454263,,852540301,Other OTC,PNK,Diagnostics & Research,https://www.stagezerolifesciences.com,"StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.",Mr. James R. Howard-Tripp,Healthcare,CA,40,,70 East Beaver Creek Road,Richmond Hill,ON,L4B 3B2,,0,https://financialmodelingprep.com/image-stock/SZLSF.png,2009-09-08,True,False,False,False,False
